Press Room

PhRMApedia Press Room

PhRMApedia's Press Room will provide the most recent press releases. Search PhRMApedia for additional press releases.  PhRMApedia is your new resource hub. You can search our entire database of media releases, reports, white papers, videos and more. Type your keywords in the search bar and explore PhRMA’s resources. Search results will appear by type, title and date.

PhRMA supports a science-based, transparent implementation of the BPCIA biosimilars pathway.

Read More

Washington, D.C. (March 3, 2015) — Today, the Partnership for Prescription Assistance (PPA), a nationwide effort sponsored by America’s biopharmaceutical research companies, unveiled a redesigned website with new features and functionality to provide patients and caregivers with faster, easier access to information on more than 475 public and private patient assistance programs.

Read More

Visit www.FromHopetoCures.org to learn more about the value medicines provide to patients, society and our economy 

Washington, D.C. – Patients and scientists from across the country are featured in the latest “From Hope to Cures” ad campaign launched today by the Pharmaceutical Research and Manufacturers of America (PhRMA), which represents the country’s leading biopharmaceutical researchers and biotechnology companies.

Read More

Washington, D.C. (February 25, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) Executive Vice President of Scientific and Regulatory Affairs Dr. Bill Chin issued the following statement today in support of legislation to prevent sequestration of prescription drug user fees:

“PhRMA strongly supports the FDA Safety Over Sequestration Act, which would exempt future Food and Drug Administration’s (FDA) user fees from sequestration.  We commend Representatives Leonard Lance (R-NJ) and Anna Eshoo (D-CA) for their continued leadership on this critical issue.

Read More

Washington, D.C. (February 25, 2015) — Today, the Pharmaceutical Research and Manufacturers of America (PhRMA) released a new report, “A Decade of Innovation in Rare Diseases,” to document the significant progress made in the last 10 years in understanding a broad range of rare diseases and translating this knowledge into groundbreaking therapies for a variety of patient populations.

The report illustrates that more than 230 new medicines to treat rare or “orphan” diseases were approved by the U.S. Food and Drug Administration (FDA) in the last decade, and there are currently more than 450 orphan drugs in development.

Read More

Washington, D.C. (February 24, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) assistant general counsel, John Murphy, issued the following statement regarding a federal court ruling that invalidated an importation law in Maine.

Read More

Washington, D.C. (February 12, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) executive vice president, Lori Reilly, issued the following statement on the Center for Medicare & Medicaid Innovation’s (CMMI) announcement of its Oncology Care Model demonstration program, which will  test a new approach for paying doctors for their care of cancer patients: 

Read More

Washington, D.C. (January 21, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO, John J. Castellani released the following statement:

Read More

Washington, D.C. (February 5, 2015) — The following statement is provided by Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO, John J. Castellani:

“We thank Chairman Goodlatte for his leadership in the effort to curb abusive practices that can arise in patent litigation and enforcement.  We look forward to reviewing this proposal and working with Congress to ensure legislation addressing patent litigation is not harmful to the patent system.

Read More

Washington, D.C. (February 5, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and Chief Executive Officer, John Castellani, provided the following statement:

“PhRMA salutes the work of Commissioner Hamburg and recognizes her significant contributions to the thoughtful regulation of medicines, including science as a basis for better regulatory decisions. For nearly six years, and to the direct benefit of patients, Commissioner Hamburg has demonstrated strong leadership and an unwavering commitment to collaboration with all stakeholders.

“We look forward to working with the FDA’s leadership and Acting Commissioner Ostroff to bring safe and effective innovative medicines to patients.”

Read More

Washington, D.C. (February 2, 2015) – Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani issued the following statement on President Barack Obama’s FY2016 budget proposal:

Read More

Washington, D.C. (January 27, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) President and Chief Executive Officer John J. Castellani issued the following statement on the newly released 21st Century Cures discussion draft: 

"We appreciate the opportunity to review the discussion draft released today and look forward to providing feedback to the House Energy and Commerce Committee.

 “PhRMA supports the Committee’s goal of accelerating the discovery, development and delivery of new medicines for patients and provided feedback on several of the 21st Century Cures whitepapers.”

About PhRMA

Read More

Washington, D.C. (January 26, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) president and chief executive officer John J. Castellani issued the following statement on Health and Human Services (HHS) Secretary Sylvia Mathews Burwell’s announcement on payment and delivery reform: 

"PhRMA supports Secretary Burwell’s goal of advancing affordable, high quality and patient centered health care, and today’s announcement represents an important step forward.

Read More

Washington, D.C. (January 22, 2015) — Pharmaceutical Research and Manufacturers of America (PhRMA) senior vice president, communications, Robert Zirkelbach released the following statement:

Read More

Washington, D.C. (December 22, 2014) — Pharmaceutical Research and Manufacturers of America (PhRMA) Deputy President, Mark Grayson issued the following statement:

"PhRMA welcomes today’s release of the U.S. International Trade Commission report on 'Trade, Investment, and Industrial Policies in India: Effects on the U.S. Economy.'  The report is useful in documenting the challenges U.S. business faces in India, but also the potential benefits to both economies from addressing existing trade barriers.  For example, the report identifies that improved IP protection would have 'substantial positive effects' on U.S. exports to India and increased economic engagement in India. 

Read More

Pages

More On PhRMA — powered by PhRMApedia